{
  "forecastId": "37657-diverse_info-gpt5-2",
  "questionId": 37657,
  "condition": "diverse_info",
  "model": "gpt5",
  "position": 2,
  "infoLabel": "info2",
  "groupId": "37657-diverse_info",
  "independentForecastId": "37657-gpt5-info2",
  "otherForecastIds": [
    "37657-pro-info1",
    "37657-sonnet-info3"
  ],
  "forecast": {
    "review": "- New arguments: Forecaster 2 cites lab evidence of human receptor usage and in vitro infection (with low efficiency). Forecaster 3 provides a base-rate estimate (~4% of novel bat CoVs yield human cases within a year) and quantifies lab-accident risk over 45 days as negligible.\n- Assessment: The short horizon remains the dominant factor. F3’s base-rate framing is helpful and supports a probability well below 2% when scaled to 45 days. F2’s receptor-binding claim could raise risk slightly if robust, but I’m cautious: HKU5-lineage merbecoviruses typically use DPP4 (not ACE2), and the specific claim may be preliminary or misattributed; either way, low entry efficiency tempers impact. Both analyses reinforce that detection-and-official-reporting by July 1 is an additional nontrivial hurdle.\n- Net: Their inputs mostly push downward due to base-rate reasoning and the short reporting window; the lab evidence keeps the forecast nonzero but not meaningfully higher.",
    "rationale": "Time remaining is ~46 days. Status quo: no human cases reported by WHO/CDC/ProMED/GISAID, despite ongoing SARI metagenomic surveillance in multiple countries—negative evidence for circulation in humans. For a Yes outcome, a rare spillover plus timely detection, sequencing tied specifically to HKU5-CoV-2 (or an unequivocally synonymous designation), and reporting by a credible source must all occur before July 1. That compound event is unlikely on this horizon.\nMechanistically, HKU5-lineage merbecoviruses have historically faced barriers to efficient human infection (often DPP4-dependent, with variable compatibility). Even if preliminary lab data suggest some human receptor usage and low-level replication, the practical near-term spillover-and-detection risk remains small. Additionally, the naming/reporting constraint (major orgs explicitly identifying HKU5-CoV-2) slightly lowers near-term odds relative to raw spillover risk.\nForecaster 3’s base-rate argument (≈0.5% scaled to 45 days) and negligible lab-accident probability further support a sub-2% estimate. Compared to my prior 2%, I’m nudging down to 1.5% to reflect these base-rate and reporting-window considerations, while keeping nonzero weight for a detected sporadic case.\nWhat would move me up: credible reports of merbecovirus-positive human SARI cases in regions linked to HKU5-CoV-2 reservoirs; lab data showing efficient use of human receptors and replication in primary human airway cells; detection in an intermediate host with close human contact.\nWhat would move me down: continued absence of signals into late June; authoritative clarification that the virus lacks human-relevant receptor compatibility; or reclassification that reduces the likelihood of timely, specific identification by WHO/CDC.\nNet: Slight downward adjustment based on base rates and reporting hurdles, with surveillance keeping a small tail risk intact.",
    "probability": 1.5
  },
  "usage": {
    "inputTokens": 1841,
    "outputTokens": 2102,
    "totalTokens": 3943,
    "reasoningTokens": 1472,
    "cachedInputTokens": 1280
  }
}